Ocugen to file for full U.S. approval of COVID-19 shot instead of EUA – Reuters

The word “COVID-19” is reflected in a drop on a syringe needle in this illustration taken November 9, 2020. REUTERS/Dado Ruvic/Illustration//File Photo

Ocugen Inc (OCGN.O) said on Thursday it would no longer pursue an emergency use authorization for its COVID-19 vaccine candidate, Covaxin, and would instead aim to file for a full U.S. approval of the shot.

Ocugen said the decision was based on a recommendation from the U.S. Food and Drug Administration (FDA), which also requested more information and data for the full approval.

The company said it expects data from an additional clinical trial will be required to support the marketing application submission for Covaxin.

“While this will extend our timelines, we are committed to bringing COVAXIN to the U.S.,” Ocugen Chief Executive Officer Dr Shankar Musunuri said.

The company is co-developing Covaxin with India-based Bharat Biotech for the U.S. market.

Ocugen recently secured exclusive rights to market the vaccine in Canada and has started discussions with Health Canada for regulatory approval, it said.

The company’s shares were down about 40% at $5.56 before the bell.

Our Standards: The Thomson Reuters Trust Principles.

Sorgente articolo:
Ocugen to file for full U.S. approval of COVID-19 shot instead of EUA – Reuters

User ID Campaign ID Link
d9a95efa0a2845057476957a427b0499 l-99999979 Ugo Fiasconaro
d9a95efa0a2845057476957a427b0499 l-99999982 Cloud Real Time
d9a95efa0a2845057476957a427b0499 l-99999993 B2B Keyword tool
d9a95efa0a2845057476957a427b0499 l-99999996 Service for LMS